



Drug Monograph

Drug/Drug **Afrezza® (insulin human) powder for inhalation/ Rapid**
 Class: **Acting Insulin**
 Prepared for: MO HealthNet
 Prepared by: Conduent-Heritage

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Afrezza® is now available in a package of 90 – 8 unit cartridges and 2 inhalers as well as 90 – 12 unit cartridges and 2 inhalers.

Manufacturer: Mannkind Corporation, Danbury, CT 06810

Indications: Afrezza® is a rapid acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

Costs: \$6.07 per 8 unit cartridge and \$9.11 per 12 unit cartridge of Afrezza® Respiclick™. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Increased Risk of ADE Under Solicitation
 Appropriate Indications Non Preferred

Prepared By: Luke Boehmer Pharm.D.
 Date: November17, 2017